Table 3.
Group | Inhibition rate (%) | ||
---|---|---|---|
SDF-1 | VEGF-C | VEGF-C + SDF-1 | |
BS | 0.00 ± 5.47 | 0.00 ± 7.28 | 0.00 ± 5.52 |
JFK-1 | 44.19 ± 5.03∗ | 32.81 ± 11.36∗ | 34.96 ± 5.41∗ |
JFK-2 | 66.03 ± 2.82∗ | 69.87 ± 3.08∗ | 67.06 ± 5.49∗ |
JFK-3 | 80.49 ± 5.27∗ | 82.22 ± 5.70∗ | 72.04 ± 2.77∗ |
AMD | 87.05 ± 3.79∗ | ||
Len | 84.69 ± 3.90∗ | ||
Len + AMD | 84.82 ± 2.09∗ |
BS, blank serum; JFK-1, JFK-2, and JFK-3, the serums prepared from rats by oral administration of JFK at doses of 1.8, 3.6, and 7.2 g/kg, respectively; AMD, AMD3100; Len, Lenvatinib. The inhibition rates of BS groups were pegged as 0.00%, and others were calculated relative to it. Data were expressed as mean ± SD, n = 3. ∗ p < 0.01 compared with the BS group, respectively.